Skip to main content
AAN.com
Brief Communications
January 11, 2000

Valproate-induced hyperammonemic encephalopathy in the presence of topiramate

January 11, 2000 issue
54 (1) 230

Abstract

Article abstract Two adult patients with focal epilepsy who tolerated valproate (VPA) well in different combinations of anticonvulsants developed hyperammonemic encephalopathy when treated with VPA in combination with topiramate (TPM). Topiramate may contribute to the increased ammonia level by its inhibition of carbonic anhydrase and cerebral glutamine synthetase, thereby facilitating VPA/TPM hyperammonemic encephalopathy. Recovery occurred after withdrawal of VPA or TPM.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Marescaux C, Warter JM, Micheletti G, Rumbach L, Coquillat G, Kurtz D. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982;23:297–305.
2.
Duarte J, Macias S, Coria F, Fernandez E, Claveria LE. Valproate-induced coma: case report and literature review. Ann Pharmacother 1993;27:582–583.
3.
Oechsner M, Steen C, Stürenburg HJ, Kohlschütter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarboamylase deficiency. J Neurol Neurosurg Psychiatr 1998;64:680–682.
4.
Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979;20:697–703.
5.
Warter JM, Marescaux C, Brandt C, et al. Sodium valproate associated with phenobarbital: effects on ammonia metabolisms in humans. Epilepsia 1983;24:628–633.
6.
Stephens JR, Levy RH. Effects of valproate and citrulline on ammonium-induced encephalopathy. Epilepsia 1994;35:164–171.
7.
Blindauer KA, Harrington G, Morris GL, Ho KC. Fulminant progression of demyelinating disease after valproate-induced encephalopathy. Neurology 1998;51:292–295.
8.
Privitera MD. Topiramate: a new antiepileptic drug. Ann Pharmacother 1997;31:1164–1173.
9.
Haussinger D, Kaiser S, Stehle T, Gerok W. Liver carbonic anhydrase and urea synthesis. The effect of diuretics. Biochem Pharmacol 1986;35:3317–3322.
10.
Fraser CM, Sills GJ, Forrest G, Thompson GG, Brodie MJ. Effects of antiepileptic drugs on glutamine synthetase activity in mouse brain. Br J Pharmacol 1999;126:1634–1638.

Information & Authors

Information

Published In

Neurology®
Volume 54Number 1January 11, 2000
Pages: 230
PubMed: 10636156

Publication History

Received: June 29, 1999
Accepted: August 21, 1999
Published online: January 11, 2000
Published in print: January 11, 2000

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

H.M. Hamer, MD
From the Department of NeurologyUniversity of Marburg, Marburg, Germany.
S. Knake, MD
From the Department of NeurologyUniversity of Marburg, Marburg, Germany.
U. Schomburg, MA
From the Department of NeurologyUniversity of Marburg, Marburg, Germany.
F. Rosenow, MD
From the Department of NeurologyUniversity of Marburg, Marburg, Germany.

Notes

Address correspondence and reprint requests to Dr. H.M. Hamer, Department of Neurology, University of Marburg, Rudolf-Bultmann-Str. 8, 35033 Marburg, Germany; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Valproic Acid–Associated Hyperammonemia, Journal of Clinical Psychopharmacology, 43, 3, (283-294), (2023).https://doi.org/10.1097/JCP.0000000000001689
    Crossref
  2. Akute und chronische organische Psychosyndrome im Kindes- und Jugendalter, Psychiatrie und Psychotherapie des Kindes- und Jugendalters, (1-47), (2023).https://doi.org/10.1007/978-3-662-49289-5_96-1
    Crossref
  3. Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine, Medicine, 101, 26, (e29780), (2022).https://doi.org/10.1097/MD.0000000000029780
    Crossref
  4. Risk factors and outcome of hyperammonaemia in people with epilepsy, Journal of Neurology, 269, 12, (6395-6405), (2022).https://doi.org/10.1007/s00415-022-11304-7
    Crossref
  5. Valproic acid–induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey, Psychopharmacology, 240, 1, (149-156), (2022).https://doi.org/10.1007/s00213-022-06289-0
    Crossref
  6. Anti-convulsant Agents: Acute Drug Therapy Outside Status Epilepticus, NeuroPsychopharmacotherapy, (3493-3516), (2022).https://doi.org/10.1007/978-3-030-62059-2_374
    Crossref
  7. Encefalopatía hiperamonémica por ácido valproico, sin elevación de transaminasas: Reporte de Caso, Revista de la Facultad de Ciencias de la Salud Universidad del Cauca, 23, 2, (58-63), (2021).https://doi.org/10.47373/rfcs.2021.v23.1823
    Crossref
  8. Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia, Frontiers in Molecular Neuroscience, 14, (2021).https://doi.org/10.3389/fnmol.2021.639145
    Crossref
  9. Valproate but not levetiracetam slows the EEG alpha peak frequency – A pharmaco-EEG study, Clinical Neurophysiology, 132, 6, (1203-1208), (2021).https://doi.org/10.1016/j.clinph.2021.02.392
    Crossref
  10. Iatrogenic (drug induced) cognitive disorders, Medical Journal of the Russian Federation, 26, 4, (248-254), (2020).https://doi.org/10.17816/0869-2106-2020-26-4-248-254
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share